title: Anti-viral drugs in continuous ambulatory peritoneal dialysis (CAPD).
abstract: The prevalence of HIV-positive subjects in dialysis (hemodialysis and peritoneal dialysis) population varies from 0.13 to 0.36% in italian and french studies, respectively. Most drugs used in HIV therapy are primarily excreted by the kidney. In patients with renal insufficiency, careful dosage adjustment is mandatory to optimize drug exposure and reduce the risk for adverse events. We review the impact of peritoneal dialysis on the pharmacokinetics of antiviral drugs, and discuss on the dosage recommendations needed to achieve efficacy and avoid toxicity in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis (CAPD).
authors.affiliation: Department of Nephrology, Pitie Salpetriere Hospital, Paris, France. hassan.izzedine@psl.ap-hop-paris.fr
authors.forename: H
authors.initials: H
authors.lastname: Izzedine
authors.forename: V
authors.initials: V
authors.lastname: Launay-Vacher
authors.forename: B
authors.initials: B
authors.lastname: Issad
authors.forename: G
authors.initials: G
authors.lastname: Deray
mesh_terms: D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000963:Antimetabolites / Q000008:administration & dosage / Q000493:pharmacokinetics; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000493:pharmacokinetics; D017245:Foscarnet / Q000008:administration & dosage / Q000493:pharmacokinetics; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D006525:Hepatitis, Viral, Human / Q000150:complications / Q000188:drug therapy; D006566:Herpesviridae Infections / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000493:pharmacokinetics; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism* / Q000628:therapy; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011485:Protein Binding; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D014777:Virus Diseases / Q000150:complications / Q000188:drug therapy*
chemical_list: D019380:Anti-HIV Agents; D000963:Antimetabolites; D000998:Antiviral Agents; D015224:Dideoxynucleosides; D017320:HIV Protease Inhibitors; D016898:Interferon-alpha; D018894:Reverse Transcriptase Inhibitors; D017245:Foscarnet; D000218:Adamantane